VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2022 | Updates from the LocoMMotion study

In this video, Hermann Einsele, MD, FRCP, University of Würzburg, Würzburg, Germany, shares some updates on the LocoMMotion study (NCT04035226). Prof. Einsele first discusses the overall survival (OS) and progression-free survival (PFS) observed, which further highlight the limited success of current treatment approaches and the importance of further investigating novel immunotherapies such as CAR-T therapy and bispecific antibodies in patients with relapsed/refractory (R/R) myeloma. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter